{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T21:19:23Z","timestamp":1771535963768,"version":"3.50.1"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2000,10,1]],"date-time":"2000-10-01T00:00:00Z","timestamp":970358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trends in Neurosciences"],"published-print":{"date-parts":[[2000,10]]},"DOI":"10.1016\/s1471-1931(00)00030-6","type":"journal-article","created":{"date-parts":[[2004,10,14]],"date-time":"2004-10-14T11:18:48Z","timestamp":1097752728000},"page":"S117-S126","source":"Crossref","is-referenced-by-count":167,"special_numbering":"S1","title":["Continuous dopamine-receptor stimulation in early Parkinson's disease"],"prefix":"10.1016","volume":"23","author":[{"given":"C. Warren","family":"Olanow","sequence":"first","affiliation":[]},{"given":"Anthony H.V.","family":"Schapira","sequence":"additional","affiliation":[]},{"given":"Olivier","family":"Rascol","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S1471-1931(00)00030-6_bib1","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1056\/NEJM199810083391506","article-title":"Parkinson's disease","volume":"339","author":"Lang","year":"1998","journal-title":"New Engl. J. Med."},{"key":"10.1016\/S1471-1931(00)00030-6_bib2","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJM199309303291408","article-title":"Drug therapy: treatment of Parkinson's disease","volume":"329","author":"Calne","year":"1993","journal-title":"New Engl. J. Med."},{"key":"10.1016\/S1471-1931(00)00030-6_bib3","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/mds.870090107","article-title":"A multi-center, double-blind, placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease","volume":"9","author":"Olanow","year":"1994","journal-title":"Mov. Disord."},{"key":"10.1016\/S1471-1931(00)00030-6_bib4","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1212\/WNL.44.5.913","article-title":"Effect of peripheral catechol-O-methyltransferase (COMT) inhibition on the pharmacokinetics and pharmacodynamics of l-dopa in parkinsonian patients","volume":"44","author":"Nutt","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/S1471-1931(00)00030-6_bib5","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/ana.410420511","article-title":"Entacapone improves motor fluctuations in l-dopa-treated Parkinson's disease patients","volume":"42","year":"1997","journal-title":"Ann. Neurol."},{"key":"10.1016\/S1471-1931(00)00030-6_bib6","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1212\/WNL.51.5.1309","article-title":"Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations","volume":"51","author":"Rinne","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/S1471-1931(00)00030-6_bib7","first-page":"167","article-title":"Preventing levodopainduced dyskinesia","volume":"47","author":"Olanow","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/S1471-1931(00)00030-6_bib8","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/0166-2236(89)90074-X","article-title":"The functional anatomy of basal ganglia disorders","volume":"12","author":"Albin","year":"1989","journal-title":"Trends Neurosci."},{"key":"10.1016\/S1471-1931(00)00030-6_bib9","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0166-2236(90)90110-V","article-title":"Primate models of movement disorders of basal ganglia origin","volume":"13","author":"DeLong","year":"1990","journal-title":"Trends Neurosci."},{"key":"10.1016\/S1471-1931(00)00030-6_bib10","first-page":"9576","article-title":"Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated","volume":"90","author":"Cepeda","year":"1993"},{"key":"10.1016\/S1471-1931(00)00030-6_bib11","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0306-4522(98)00604-6","article-title":"Opposing modulation of cortical NMDA receptor-mediated responses by low and high concentrations of dopamine","volume":"91","author":"Zheng","year":"1999","journal-title":"Neuroscience"},{"key":"10.1016\/S1471-1931(00)00030-6_bib12","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1152\/jn.1994.72.2.507","article-title":"The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism","volume":"72","author":"Bergman","year":"1994","journal-title":"J. Neurophysiol."},{"key":"10.1016\/S1471-1931(00)00030-6_bib13","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/0028-3908(85)90070-X","article-title":"Regional brain uptake of 2-deoxy glucose in MPTP-induced parkinsonism in the Macaque monkey","volume":"24","author":"Crossman","year":"1985","journal-title":"Neuropharmacology"},{"key":"10.1016\/S1471-1931(00)00030-6_bib14","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/jcbfm.1994.99","article-title":"Metabolic topography of parkinsonism","volume":"14","author":"Eidelberg","year":"1994","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/S1471-1931(00)00030-6_bib15","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S1471-1931(00)00028-8","article-title":"Pathophysiology of the basal ganglia in Parkinson's disease","volume":"23","author":"Obeso","year":"2000","journal-title":"Trends Neurosci."},{"key":"10.1016\/S1471-1931(00)00030-6_bib16","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/0006-8993(95)01017-P","article-title":"Single striatofugal axons arborizing in both pallidal segments and in the substantia nigra in primates","volume":"698","author":"Parent","year":"1995","journal-title":"Brain Res."},{"key":"10.1016\/S1471-1931(00)00030-6_bib17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/(SICI)1096-9861(20000131)417:1<17::AID-CNE2>3.0.CO;2-I","article-title":"Single-axon tracing study of neurons of the external segment of the globus pallidus in primate","volume":"417","author":"Sato","year":"2000","journal-title":"J. Comp. Neural."},{"key":"10.1016\/S1471-1931(00)00030-6_bib18","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/72929","article-title":"Anatomical and physiological evidence for Dl and D2 dopamine receptor colocalization in neostriatal neurons","volume":"3","author":"Aizman","year":"2000","journal-title":"Nat. Neurosci."},{"key":"10.1016\/S1471-1931(00)00030-6_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1098-2396(199907)33:1<1::AID-SYN1>3.0.CO;2-G","article-title":"Alterations in electrophysiological activity and dye coupling of striatal spiny and aspiny neurons in dopamine-denervated rat striatum recorded in vivo","volume":"31","author":"Onn","year":"1999","journal-title":"Synapse"},{"key":"10.1016\/S1471-1931(00)00030-6_bib20","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1152\/jn.1994.71.5.1917","article-title":"Dye coupling between rat striatal neurons recorded in vivo: compartmental organization and modulation by dopamine","volume":"71","author":"Onn","year":"1994","journal-title":"J. Neurophysiol."},{"key":"10.1016\/S1471-1931(00)00030-6_bib21","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1126\/science.2402638","article-title":"Reversal of experimental parkinsonism by lesions of the subthalamic nucleus","volume":"249","author":"Bergman","year":"1990","journal-title":"Science"},{"key":"10.1016\/S1471-1931(00)00030-6_bib22","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/mds.870060208","article-title":"Alleviation of parkinsonism by antagonist of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate","volume":"6","author":"Brotchie","year":"1991","journal-title":"Mov. Disord."},{"key":"10.1016\/S1471-1931(00)00030-6_bib23","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1056\/NEJM199710093371503","article-title":"Posteroventral medial pallidotomy in advanced Parkinson's disease","volume":"337","author":"Lang","year":"1997","journal-title":"New Engl. J. Med."},{"key":"10.1016\/S1471-1931(00)00030-6_bib24","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJM199810153391603","article-title":"Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease","volume":"339","author":"Limousin","year":"1998","journal-title":"New Engl. J. Med."},{"key":"10.1016\/S1471-1931(00)00030-6_bib25","unstructured":"Olanow, C.W. and Brin, M.F. Surgery for Parkinson's disease: a physician's perspective. Adv. Neurol. (in press)"},{"key":"10.1016\/S1471-1931(00)00030-6_bib26","first-page":"22","article-title":"Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with current models of the basal ganglia","volume":"47","author":"Obeso","year":"2000","journal-title":"Ann. Neural."},{"key":"10.1016\/S1471-1931(00)00030-6_bib27","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1152\/jn.1992.68.5.1859","article-title":"Excitotoxic acid lesions of the primate subthalamic nucleus result in reduced pallidal neuronal activity during active holding","volume":"68","author":"Hamada","year":"1992","journal-title":"J. Neurophysiol."},{"key":"10.1016\/S1471-1931(00)00030-6_bib28","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0306-4522(94)00484-M","article-title":"Activity of pallidal neurons in the monkey during dyskinesia induced by injection of bicuculline in the external pallidum","volume":"65","author":"Matsumura","year":"1995","journal-title":"Neuroscience"},{"key":"10.1016\/S1471-1931(00)00030-6_bib29","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/ana.410420513","article-title":"Effects of apomorphine on globus pallidus neurons in Parkinsonian patients","volume":"42","author":"Hutchison","year":"1997","journal-title":"Ann. Neurol."},{"key":"10.1016\/S1471-1931(00)00030-6_bib30","series-title":"Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia","first-page":"809","article-title":"A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain","volume":"115","author":"Mitchell","year":"1992"},{"key":"10.1016\/S1471-1931(00)00030-6_bib31","first-page":"S122","article-title":"Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications","volume":"47","author":"Chase","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/S1471-1931(00)00030-6_bib32","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0166-2236(90)90106-K","article-title":"The neuronal network of the basal ganglia as revealed by the study of synaptic connections of identified neurons","volume":"13","author":"Smith","year":"1990","journal-title":"Trends Neurosci."},{"key":"10.1016\/S1471-1931(00)00030-6_bib33","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/ana.410390505","article-title":"Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys","volume":"39","author":"Papa","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/S1471-1931(00)00030-6_bib34","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1212\/WNL.50.5.1323","article-title":"Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease","volume":"50","author":"Verhagen Metman","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/S1471-1931(00)00030-6_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0306-4522(91)90196-U","article-title":"Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia","volume":"41","author":"Grace","year":"1991","journal-title":"Neuroscience"},{"key":"10.1016\/S1471-1931(00)00030-6_bib36","first-page":"1","article-title":"Predictive reward signal of dopamine neurons","volume":"80","author":"Schultz","year":"1998","journal-title":"J. Neurosci."},{"key":"10.1016\/S1471-1931(00)00030-6_bib37","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/ana.410250509","article-title":"Continuous and intermittent levodopa differentially affect basal ganglia function","volume":"25","author":"Juncos","year":"1989","journal-title":"Ann. Neural."},{"key":"10.1016\/S1471-1931(00)00030-6_bib38","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/ana.410310514","article-title":"Selective D2 receptor stimulation induces dyskinesia in parkinsonian monkeys","volume":"31","author":"Luquin","year":"1992","journal-title":"Ann. Neurol."},{"key":"10.1016\/S1471-1931(00)00030-6_bib39","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0014-4886(92)90125-A","article-title":"Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys","volume":"117","author":"Gomez-Mancilla","year":"1992","journal-title":"Exp. Neural."},{"key":"10.1016\/S1471-1931(00)00030-6_bib40","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/mds.870110117","article-title":"Dyskinesia and wearing-off following dopamine Dl treatment in drug-naive 1-methyl-4-phenyl-1,2,3,-6-tetrahydropyridine-lesioned primates","volume":"11","author":"Blanchet","year":"1996","journal-title":"Mov. Disord."},{"key":"10.1016\/S1471-1931(00)00030-6_bib41","series-title":"Correlation with [3H] spiperone binding","first-page":"294","article-title":"Chronic treatment with levodopa, but not bromocriptine induces dyskinesia in MPTP-treated parkinsonian monkeys","volume":"379","author":"B\u00e9dard","year":"1986"},{"key":"10.1016\/S1471-1931(00)00030-6_bib42","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0014-2999(88)90750-9","article-title":"Behavioral and biochemical effect of chronic treatment with Dl and\/or D2 dopamine agonists in MPTP monkeys","volume":"150","author":"Falardeau","year":"1988","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/S1471-1931(00)00030-6_bib43","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0014-2999(90)94802-5","article-title":"Effect of chronic treatment of MPTP monkeys with dopamine Dl and\/or D2 receptor agonists","volume":"178","author":"Gagnon","year":"1990","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/S1471-1931(00)00030-6_bib44","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/0006-8993(96)00597-5","article-title":"Dopamine D1 receptor mRNA and receptor levels in striatum of MPTP monkeys chronically treated with SKF-82958","volume":"735","author":"Grondin","year":"1996","journal-title":"Brain Res."},{"key":"10.1016\/S1471-1931(00)00030-6_bib45","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/mds.870130207","article-title":"De novo administration of ropinirole and bromocriptine induces less dyskinesia than levodopa in MPTP-treated marmoset","volume":"13","author":"Pearce","year":"1998","journal-title":"Mov. Disord."},{"key":"10.1016\/S1471-1931(00)00030-6_bib46","first-page":"854","article-title":"Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys","volume":"272","author":"Blanchet","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/S1471-1931(00)00030-6_bib47","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0014-2999(99)00482-3","article-title":"Dopamine D1 receptor mRNA and receptor levels in striatum of MPTP monkeys chronically treated with SKF-82958","volume":"378","author":"Grondin","year":"1999","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/S1471-1931(00)00030-6_bib48","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0306-4522(96)00689-6","article-title":"Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive, 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: in situ hybridization histochemical analysis","volume":"79","author":"Goulet","year":"1997","journal-title":"Neuroscience"},{"key":"10.1016\/S1471-1931(00)00030-6_bib49","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0169-328X(97)00123-X","article-title":"Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with l-dopa therapy","volume":"49","author":"Morisette","year":"1997","journal-title":"Mol. Brain Res."},{"key":"10.1016\/S1471-1931(00)00030-6_bib50","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1046\/j.1471-4159.1999.0720682.x","article-title":"Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists","volume":"72","author":"Morisette","year":"1999","journal-title":"J. Neurochem."},{"key":"10.1016\/S1471-1931(00)00030-6_bib51","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1460-9568.1996.tb01220.x","article-title":"Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum","volume":"8","author":"Doucet","year":"1996","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/S1471-1931(00)00030-6_bib52","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S1471-1931(00)00025-2","article-title":"Dopamine receptors: from structure to behavior","volume":"23","author":"Scalfon","year":"2000","journal-title":"Trends Neurosci."},{"key":"10.1016\/S1471-1931(00)00030-6_bib53","first-page":"173","article-title":"Treatment of Parkinson's disease with l-dopa and R-4602: review and present status","volume":"2","author":"Barbeau","year":"1973","journal-title":"Adv. Neural."},{"key":"10.1016\/S1471-1931(00)00030-6_bib54","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1126\/science.6332378","article-title":"Chronic parkinsonism in humans due to a product of meperidine analog synthesis","volume":"225","author":"Langston","year":"1984","journal-title":"Science"},{"key":"10.1016\/S1471-1931(00)00030-6_bib55","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/ana.410390504","article-title":"The response to levodopa in Parkinson's disease: imposing pharmacologic law and order","volume":"39","author":"Nutt","year":"1996","journal-title":"Ann. Neural."},{"issue":"Suppl. 1","key":"10.1016\/S1471-1931(00)00030-6_bib56","first-page":"9","article-title":"l-dopa and dyskinesias in normal monkeys","volume":"14","author":"Pearce","year":"1999","journal-title":"Mov. Disord."},{"key":"10.1016\/S1471-1931(00)00030-6_bib57","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1136\/jnnp.57.9.1034","article-title":"A randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow-up","volume":"57","author":"Montastruc","year":"1994","journal-title":"J. Neural. Neurosurg. Psychiatry"},{"key":"10.1016\/S1471-1931(00)00030-6_bib58","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1212\/WNL.37.5.826","article-title":"Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up","volume":"37","author":"Rinne","year":"1987","journal-title":"Neurology"},{"key":"10.1016\/S1471-1931(00)00030-6_bib59","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","article-title":"A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa","volume":"342","author":"Rascal","year":"2000","journal-title":"New Engl. J. Med."},{"issue":"Suppl. 1","key":"10.1016\/S1471-1931(00)00030-6_bib60","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/00003495-199855001-00004","article-title":"Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications","volume":"55","author":"Rinne","year":"1998","journal-title":"Drugs"},{"issue":"Suppl. 3","key":"10.1016\/S1471-1931(00)00030-6_bib61","first-page":"S4","article-title":"Pramipexole versus levodopa in early Parkinson's disease: the randomized controlled CALM-PD trial","volume":"15","author":"Shoulson","year":"2000","journal-title":"Mov. Disord."},{"issue":"Suppl. 3","key":"10.1016\/S1471-1931(00)00030-6_bib62","first-page":"S4","article-title":"Pergolide vs l-dopa (PELMOPET)","volume":"15","author":"Oertel","year":"2000","journal-title":"Mov. Disord."},{"key":"10.1016\/S1471-1931(00)00030-6_bib63","first-page":"S90","article-title":"Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates","volume":"47","author":"Jenner","year":"2000","journal-title":"Ann. Neural."},{"key":"10.1016\/S1471-1931(00)00030-6_bib64","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/0009-9236(95)90035-7","article-title":"Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltrasferase inhibitor tolcapone during first administration to humans","volume":"57","author":"Dingemanse","year":"1995","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/S1471-1931(00)00030-6_bib65","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/BF00199880","article-title":"Inhibition of catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone","volume":"46","author":"Ker\u00e4nen","year":"1994","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/S1471-1931(00)00030-6_bib66","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1212\/WNL.44.7.1292","article-title":"The effect of entacapone (OR-611) on brain 18F-6-l-fluorodopa metabolism: implications for levodopa therapy in Parkinson's disease","volume":"44","author":"Sawle","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/S1471-1931(00)00030-6_bib67","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1212\/WNL.48.1.81","article-title":"Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations","volume":"48","author":"Kurth","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/S1471-1931(00)00030-6_bib68","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1212\/WNL.51.5.1309","article-title":"Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations","volume":"51","author":"Rinne","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/S1471-1931(00)00030-6_bib69","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/WNL.49.4.1066","article-title":"Tolcapone improves motor function in parkinsonian patients with the \u2018wearing off\u2019 phenomenon: a double-blind, placebo-controlled, multicenter trial","volume":"49","author":"Rajput","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/S1471-1931(00)00030-6_bib70","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/ana.410420511","article-title":"Entacapone improved motor fluctuations in levodopa-treated Parkinson's disease patients","volume":"42","year":"1997","journal-title":"Ann. Neural."},{"key":"10.1016\/S1471-1931(00)00030-6_bib71","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/jnnp.60.1.36","article-title":"Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations","volume":"60","author":"Ruottinen","year":"1996","journal-title":"J. Neural. Neurosurg. Psychiatry"},{"key":"10.1016\/S1471-1931(00)00030-6_bib72","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1001\/archneur.57.2.263","article-title":"Tolcapone (tasmar) and hepatotoxicity","volume":"57","author":"Olanow","year":"2000","journal-title":"Arch. Neural."},{"key":"10.1016\/S1471-1931(00)00030-6_bib73","unstructured":"Olanow, C.W. and Obeso, J.A. COMT inhibition in Parkinson's disease. Neurology (in press)"},{"key":"10.1016\/S1471-1931(00)00030-6_bib74","unstructured":"Olanow, C.W. and Obeso, J.A. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors. Neurology (in press)"}],"container-title":["Trends in Neurosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471193100000306?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471193100000306?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,2]],"date-time":"2019-02-02T22:28:11Z","timestamp":1549146491000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471193100000306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,10]]},"references-count":74,"alternative-id":["S1471193100000306"],"URL":"https:\/\/doi.org\/10.1016\/s1471-1931(00)00030-6","relation":{},"ISSN":["0166-2236"],"issn-type":[{"value":"0166-2236","type":"print"}],"subject":[],"published":{"date-parts":[[2000,10]]}}}